News & Updates

The selective, oral, central nervous system-penetrant reversible RIPK1 inhibitor SAR443820 appears to have limited clinical benefit in amyotrophic lateral sclerosis (ALS) and is even associated with greater hepatic enzyme increase, according to the phase II HIMALAYA trial.

Treatment with aficamten significantly improves patient-reported health status and exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), according to the ACACIA-HCM trial presented at ESC 2026.

Offsprings of women with polycystic ovarian syndrome (PCOS) – renamed as polyendocrine metabolic ovarian syndrome (PMOS) since May 2026 – exhibit cardiometabolic and reproductive alterations in young adulthood, researchers from the Chinese University of Hong Kong (CUHK) have reported.

Treatment with tirzepatide does not appear to be associated with atrial fibrillation or atrial arrhythmia in individuals with overweight or obesity, according to a meta-analysis.

In individuals with untreated HIV-1 infection, the two-drug dolutegravir/lamivudine (DTG/3TC) antiretroviral therapy (ART) regimen has similar efficacy as the three-drug bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen, according to the phase IIIb VOGUE study.

A 10-year study in Japan has found that the seasonality of Kawasaki Disease (KD) has not returned to the usual winter-dominant pattern even after lifting the COVID-19 infection mitigation measures.

Patterns of thyroid-stimulating hormone (TSH) test show no substantial difference between type 2 diabetes patients treated with GLP-1 RAs and those who received SGLT-2 inhibitors, a study has found.